Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Google Secures Pentagon AI Deal for Classified Projects 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
VANCOUVER, British Columbia, May 03, 2017 -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that management will host a conference call and audio webcast on Tuesday, May 9, 2017 at 8:30 a.m. Eastern Time to provide a business update and review first quarter 2017 financial results.
To participate, please dial (866) 516-3002 (domestic) or (760) 298-5082 (international). A live webcast will be available in the “Investors” section of Novelion’s website, www.novelion.com, and a replay will be available for 90 days after the conclusion of the event.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Amanda Murphy, Director, Investor & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
